Galderma reported first-half 2024 net sales of $3.134 billion, up 24.6% year-over-year at constant currency, and raised its full-year guidance. The performance reflects robust demand for its toxin (Dysport, Azzalure) and filler (Restylane) portfolios, particularly in international markets.
Market
Galderma Raises Full-Year Guidance After Record First-Half Sales of $3.13B
Swiss aesthetics giant posts 24.6% YoY growth and lifts outlook, signaling strong demand across toxins and fillers despite market headwinds.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Galderma's 24.6% YoY growth and raised guidance suggest the injectables market is still expanding, not consolidating.
The upgrade is significant because Galderma is the only pure-play aesthetics company among the major toxin/filler manufacturers—AbbVie is pharma-diversified, Evolus is smaller and more volatile. Strong H1 results suggest the injectables market is not saturated despite price compression and increased competition from Hugel, Revance, and private-label toxins. Galderma's guidance lift typically signals confidence in Q3–Q4 volume and pricing power. For practices, this matters as a bellwether: if Galderma is growing at 24%+, the overall market is healthy, which usually means rebate programs remain competitive and supply chains stay stable.
Source: original report ↗
Frequently asked questions
Is the injectables market saturated or still growing?
No—Galderma's 24.6% YoY growth in H1 2024 and guidance raise prove the market is still expanding despite price compression and new competitors like Hugel and Revance. Strong international demand for toxins and fillers shows there's room for volume growth, not just market share shuffling.
What does Galderma's guidance raise mean for med spa supply costs?
Galderma's confidence signals the overall market is healthy, which typically keeps rebate programs competitive and supply chains stable. When the category leader grows 24%+, practices usually maintain favorable pricing and don't face sudden shortages or margin pressure.
Why is Galderma a better market indicator than AbbVie or Evolus?
Galderma is the only pure-play aesthetics company among major toxin/filler makers—AbbVie is diversified across pharma, and Evolus is smaller and more volatile. This makes Galderma's results a cleaner read on actual injectable demand and pricing trends.
Which Galderma products drove the $3.13B first-half sales?
Dysport and Azzalure (toxins) and Restylane (fillers) led growth, with particularly strong performance in international markets. The company didn't break out exact product splits, but these three portfolios are Galderma's core revenue drivers.
How much did Galderma grow in the first half of 2024?
Galderma posted $3.134 billion in net sales for H1 2024, representing 24.6% year-over-year growth at constant currency. The company raised full-year guidance based on this momentum.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.